Ascletis receives FDA clearance to begin Phase III ASC30 programme
The Phase III programme includes two trials enrolling 4,600 participants with obesity or overweight in the US, Canada, and Europe.
News
Moleculin reports interim results from MIRACLE trial in r/r AML patients
Evommune begins Phase IIb trial of EVO756 for migraine
Estrella activates new site in Texas for STARLIGHT-1 Phase I/II trial
Atea reports positive topline results in Phase III hepatitis C study
AstraZeneca reports Phase III results for Ultomiris and Sone-Ve
First patient dosed in Estrella’s STARLIGHT-1 Phase I/II trial
Dosing commences in Bio-Thera’s Phase I solid tumour study of BAT8013
